Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**7acc1** is a small molecule inhibitor that specifically blocks lactate influx—but not efflux—through monocarboxylate transporters MCT1 and MCT4 in tumor cells. It acts by selectively interfering with the lactate uptake process, thereby altering metabolic dynamics in the lactate-rich tumor microenvironment. This specificity is unique compared to other MCT inhibitors, which tend to block both influx and efflux. 7acc1 has demonstrated anti-tumor activity in mouse models of cervical, colorectal, and breast cancers through delayed tumor growth and reduced relapse after chemotherapy. The compound enhances immune cell (NK cell) activity in vivo, further contributing to anti-cancer effects. Its molecular structure is 7-(diethylamino)-2-oxochromene-3-carboxylic acid, and its CAS number is 50995-74-9[1][3][4][8][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7acc1.